微生物驱动的肠血管屏障破坏是NASH发生的先决条件
该研究在C57BL/6J小鼠中使用高脂饮食或蛋氨酸胆碱缺乏饮食构建NASH模型,结合遗传和药物干预调节肠道屏障完整性。研究发现肠上皮屏障和肠血管屏障(GVB)破坏是NASH发病的早期事件,饮食诱导的菌群失调驱动GVB损伤和细菌易位至肝脏,而法尼醇X受体激动剂奥贝胆酸(OCA)通过激活内皮细胞β-catenin保护GVB并防止NASH进展。
要点
- 肠上皮屏障和肠血管屏障破坏是NASH发病的早期事件。
- 高脂饮食仅1周即诱导菌群失调,驱动GVB损伤和细菌易位至肝脏。
- OCA通过内皮细胞β-catenin激活保护GVB,预防和治疗NASH。
核心结论
- GVB破坏导致细菌或细菌产物易位至血液循环,是NASH发生的新机制。
- 靶向内皮细胞β-catenin激活(如OCA给药)可保护GVB并防止NASH发生。
研究设计与样本
- C57BL/6J小鼠喂食高脂饮食或蛋氨酸胆碱缺乏饮食1周或更长时间以重现NASH特征(脂肪变性、炎症、胰岛素抵抗)。
- 采用遗传和药物策略调节肠道屏障完整性。
- 将高脂饮食喂养小鼠的粪便微生物移植至无特定病原体受体小鼠。
主要发现
- 高脂饮食仅1周即诱导饮食相关菌群失调,驱动GVB损伤和细菌易位至肝脏。
- 来自高脂饮食喂养小鼠的粪便微生物移植至无特定病原体受体后,诱导GVB损伤和附睾脂肪组织增大。
- GVB破坏依赖于WNT/β-catenin信号通路干扰;仅在内皮细胞驱动β-catenin激活的遗传干预可防止GVB破坏和NASH发生。
- OCA驱动内皮细胞β-catenin激活,作为预防和治疗药物均保护GVB免受破坏。
- NASH患者结肠中GVB渗漏标志物上调。
关键数值与推荐
- 高脂饮食喂养仅1周即可发生饮食诱导的菌群失调并驱动GVB损伤。
- OCA作为预防和治疗药物均保护GVB免受破坏。
- NASH患者结肠中GVB渗漏标志物上调。
临床怎么用
- 恢复内皮细胞β-catenin激活(如OCA给药)可保护GVB损伤并防止NASH发生,为OCA用于NASH预防或治疗提供进一步证据。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fatty liver disease, including non-alcoholic fatty liver (NAFLD) and steatohepatitis (NASH), has been associated with increased intestinal barrier permeability and translocation of bacteria or bacterial products into the blood circulation. In this study, we aimed to unravel the role of both intestinal barrier integrity and microbiota in NAFLD/NASH development. METHODS: C57BL/6J mice were fed with high-fat diet (HFD) or methionine-choline-deficient diet for 1 week or longer to recapitulate aspects of NASH (steatosis, inflammation, insulin resistance). Genetic and pharmacological strategies were then used to modulate intestinal barrier integrity. RESULTS: We show that disruption of the intestinal epithelial barrier and gut vascular barrier (GVB) are early events in NASH pathogenesis. Mice fed HFD for only 1 week undergo a diet-induced dysbiosis that drives GVB damage and bacterial translocation into the liver. Fecal microbiota transplantation from HFD-fed mice into specific pathogen-free recipients induces GVB damage and epididymal adipose tissue enlargement. GVB disruption depends on interference with the WNT/β-catenin signaling pathway, as shown by genetic intervention driving β-catenin activation only in endothelial cells, preventing GVB disruption and NASH development. The bile acid analogue and farnesoid X receptor agonist obeticholic acid (OCA) drives β-catenin activation in endothelial cells. Accordingly, pharmacologic intervention with OCA protects against GVB disruption, both as a preventive and therapeutic agent. Importantly, we found upregulation of the GVB leakage marker in the colon of patients with NASH. CONCLUSIONS: We have identified a new player in NASH development, the GVB, whose damage leads to bacteria or bacterial product translocation into the blood circulation. Treatment aimed at restoring β-catenin activation in endothelial cells, such as administration of OCA, protects against GVB damage and NASH development. LAY SUMMARY: The incidence of fatty liver disease is reaching epidemic levels in the USA, with more than 30% of adults having NAFLD (non-alcoholic fatty liver disease), which can progress to more severe non-alcoholic steatohepatitis (NASH). Herein, we show that disruption of the intestinal epithelial barrier and gut vascular barrier are early events in the development of NASH. We show that the drug obeticholic acid protects against barrier disruption and thereby prevents the development of NASH, providing further evidence for its use in the prevention or treatment of NASH.
引用
- Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019. PMID: 31419514. doi:10.1016/j.jhep.2019.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。